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Background: The current biomarkers alpha-fetoprotein and human chorionic gonadotropin have limited sensitivity and specificity
for diagnosing malignant germ-cell tumours (GCTs). MicroRNAs (miRNAs) from the miR–371–373 and miR–302/367 clusters are
overexpressed in all malignant GCTs, and some of these miRNAs show elevated serum levels at diagnosis. Here, we developed a
robust technical pipeline to quantify these miRNAs in the serum and cerebrospinal fluid (CSF). The pipeline was used in samples
from a cohort of exclusively paediatric patients with gonadal and extragonadal malignant GCTs, compared with appropriate
tumour and non-tumour control groups.
Methods: We developed a method for miRNA quantification that enabled sample adequacy assessment and reliable data
normalisation. We performed qRT–PCR profiling for miR–371–373 and miR–302/367 cluster miRNAs in a total of 45 serum and CSF
samples, obtained from 25 paediatric patients.
Results: The exogenous non-human spike-in cel–miR–39–3p and the endogenous housekeeper miR–30b–5p were optimal for
obtaining robust serum and CSF qRT–PCR quantification. A four-serum miRNA panel (miR–371a–3p, miR–372–3p, miR–373–3p
and miR–367–3p): (i) showed high sensitivity/specificity for diagnosing paediatric extracranial malignant GCT; (ii) allowed early
detection of relapse of a testicular mixed malignant GCT; and (iii) distinguished intracranial malignant GCT from intracranial
non-GCT tumours at diagnosis, using CSF and serum samples.
Conclusions: The pipeline we have developed is robust, scalable and transferable. It potentially promises to improve clinical
management of paediatric (and adult) malignant GCTs.
Germ-cell tumours (GCTs) are characterised by clinical and
pathological heterogeneity. They occur from the neonatal period
through to late adulthood and arise at gonadal or extragonadal
sites, including the central nervous system. Malignant GCTs are
classified into germinoma and non-germinomatous tumours (yolk sac
tumour (YST), embryonal carcinoma (EC) and choriocarcinoma
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(CHC)), while teratomas (which show extensive somatic differ-
entiation) are generally considered benign (Palmer et al, 2010).
The utility of the conventional body fluid protein biomarkers
alpha-fetoprotein (AFP) and human chorionic gonadotropin
(HCG) for diagnosis and follow-up is restricted to specific
malignant GCT subtypes, as levels are raised predominantly in
tumours containing YST and CHC, respectively (Murray and
Nicholson, 2011). Moreover, both AFP and HCG can be elevated
in non-malignant conditions (Murray et al, 2015a). The initial
management of primary gonadal GCTs is complete resection
where possible, regardless of serum AFP/HCG levels, thus enabling
a histopathological diagnosis. For extragonadal primary sites of
disease (e.g., the retroperitoneum and mediastinum), typical
radiological findings and raised AFP/HCG markers alone may be
sufficient for diagnosis, and indeed for intracranial GCTs, this is
the recommended practice in Europe and North America
(Nicholson et al, 2002). For ‘marker-negative’ extragonadal
cases, however, biopsy is required to establish a formal
histopathological diagnosis. Such procedures carry risks of
morbidity, due to the difficulties in surgical access to these
anatomical sites. Furthermore, disease-monitoring after malig-
nant GCT diagnosis to detect early non-symptomatic relapse
currently relies heavily on serial radiological imaging, with
associated cumulative radiation exposure and second malignant
neoplasm risk (Tarin et al, 2009). Consequently, body fluid
biomarkers that offer greater sensitivity and specificity for
diagnosing and/or monitoring malignant GCTs would be of
major clinical benefit (Murray et al, 2015a).
The ideal biomarker for malignant GCTs would be: stable
within body fluids; abundant compared with levels in individuals
who were healthy, had benign GCTs or non-GCT pathology; and
present regardless of patient age (paediatric or adult), anatomical
site of disease (gonadal or extragonadal, including intracranial) or
histological subtype (e.g., YST, germinoma and EC) (Murray and
Coleman, 2012). Recent years have seen the emergence of
microRNAs (miRNAs) as a new generation of biomarkers in
malignant GCTs (Murray and Coleman, 2012). MicroRNAs are
short, non-protein coding RNAs that are highly stable and well-
suited for disease diagnosis and monitoring (Mitchell et al, 2008).
We previously demonstrated that the eight main miRNAs from the
miR–371–373 and miR–302/367 clusters were overexpressed in all
malignant GCT tissues (Palmer et al, 2010). By using a multiplexed
qRT–PCR protocol, we identified that levels of miRNAs from these
two clusters were elevated in the serum of a paediatric patient at
the time of diagnosis of an extragonadal malignant GCT, with
levels falling and remaining low during uneventful clinical follow-
up (Murray et al, 2011b). In the same year, we confirmed
these serum findings in extracranial malignant GCTs across a
range of representative ages (paediatric and adult), anatomical
sites (gonadal and extragonadal) and histological subtypes (YST,
germinoma and EC), the majority of which were AFP/HCG
marker-negative (Murray et al, 2011a; Murray and Coleman,
2012).
Although our serum miRNA findings in malignant GCTs have
since been confirmed and extended, the published studies have
exclusively (Belge et al, 2012; Dieckmann et al, 2012; Rijlaarsdam
et al, 2015; Spiekermann et al, 2015a; Syring et al, 2015) or
predominantly (Gillis et al, 2013) involved adult testicular
tumours. In such cases, a consensus panel of four serum miRNAs
from the miR–371–373 and miR–302/367 clusters (namely miR–
371a–3p, miR–372–3p, miR–373–3p and miR–367–3p) has been
shown to be highly sensitive and specific for detecting malignant
GCTs (Gillis et al, 2013; Syring et al, 2015). The present study
represents the first systematic interrogation of expression of these
miRNA clusters in serum/cerebrospinal fluid (CSF) samples from
patients with paediatric malignant GCTs. Our analysis included
serum levels at diagnosis for both ovarian and testicular disease,
early detection of relapse and levels in CSF and serum in
intracranial disease. Our investigation of the utility of these
miRNAs is underpinned by the development of a robust pipeline
for their quantification, including essential quality control (QC)
steps. The pipeline is scalable, transferable and suitable for
widespread adoption into routine clinical practice.
MATERIALS AND METHODS
The study received approval from the Multicentre Research Ethics
Committee (reference 02/4/71) and Cambridge Local Research
Ethics Committee (reference 01/128), and was performed with full
informed parental consent. All experimental steps were compliant
with the minimum information for publication of quantitative real-
time PCR experiments (MIQE; Bustin et al, 2009). Full details are
available on request.
Patient demographics and tumours analysed. In total, we
analysed 45 body fluid samples (serum n¼ 41, CSF n¼ 4), from
a cohort of 25 paediatric patients (0–16 years; Table 1). The cohort
comprised a malignant GCT group (n¼ 8; extracranial (n¼ 5) and
intracranial (n¼ 3)); a combined group comprising benign GCTs
and non-GCT tumours (n¼ 12; extracranial (n¼ 10) and intra-
cranial (n¼ 2)), and a group of control subjects without tumours
(n¼ 5). The five extracranial malignant GCTs represented gonadal
(three testicular, one ovarian) and extragonadal (sacrococcygeal)
disease. The three intracranial malignant GCTs represented two
suprasellar site (one germinoma, one non-germinoma) and one
pineal site (germinoma). The benign GCTs (n¼ 5) comprised
three immature teratomas (ITs) and two mature teratomas (MTs),
from both gonadal (n¼ 4) and extragonadal (n¼ 1) sites. The sites
of the non-GCT tumours (n¼ 6) were testicular/paratesticular
(n¼ 2; one sex cord stromal tumour, one rhabdomyosarcoma),
ovarian (n¼ 2; one simple cyst, one small cell carcinoma of the
ovary, hypercalcaemic type (Bailey et al, 2015)) and intracranial
(n¼ 2; one suprasellar WHO grade 1 ganglioglioma and one
disseminated MYCN-amplified neuroblastoma). The five samples
in the control group were from five age- and gender-matched
anonymised subjects, as described previously (Murray et al,
2015b). There were no statistical differences in age between the
three patient groups. Full clinicopathological details are given in
Table 1.
Overview of pipeline development. The pipeline developed for
robust serum miRNA quantification is shown in Figure 1.
Components of this pipeline are described in the following
sections, with reference to the various colour-coded boxes in
Figure 1.
Sample processing and RNA extraction. As part of each patient’s
standard clinical care, blood was sampled in serum separator tubes
and CSF was collected in plain tubes (Table 1). All specimens were
sent to the routine clinical biochemistry diagnostic laboratories at
Addenbrooke’s Hospital, Cambridge, UK, where they were
processed and centrifuged within 4 h of receipt. After being used
for routine clinical measurements, samples were kept refrigerated
at 4 1C for up to 3 days before residual serum/CSF was retrieved
and then frozen and stored at  80 1C. At each stage, all samples
were processed according to good clinical and laboratory practice,
including the use of disposable pipette tips. Only samples without
macroscopic evidence of haemolysis were used (Murray et al,
2015b), to avoid substantial technical variation due to the release of
intracellular miRNAs from red blood cells (Kirschner et al, 2011;
Figure 1, box A).
RNA isolation. RNA from 200 ml of thawed serum or CSF
samples was isolated using the miRNeasy serum kit (Qiagen,
Crawley, UK), according to the manufacturer’s instructions.
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In order to increase RNA yield, we first added MS2 carrier RNA
(Roche, Welwyn Garden City, UK) to QIAzol to give a final
concentration of 1.25 mgml 1 (Murray et al, 2015b). To measure
the RNA extraction efficiency, we also made a master mix of the
exogenous non-human spike-in cel–miR–39–3p from the kit
and added a fixed quantity (5.6 108 copies) to each sample
(Murray et al, 2014), as per the manufacturer’s instructions. This
fixed quantity resulted in subsequent cel–miR–39–3p qRT–PCR
levels within the expected range for endogenous human serum
miRNA levels (Murray et al, 2014). For samples where 200 ml was
Table 1. Clinicopathological details of samples and patients analysed
Sample Cancer type Code Gender
Age (years) at
diagnosis Site
Days since
diagnosis
Serum
sample
CSF
sample
1 N/A CONT_1 Male 13 N/A 0 Yes No
2 N/A CONT_2 Female 2 N/A 0 Yes No
3 N/A CONT_3 Female 11 N/A 0 Yes No
4 N/A CONT_4 Male 1 N/A 0 Yes No
5 N/A CONT_5 Female 7 N/A 0 Yes No
6 MT BGCT_ExC#1 Male 4 Testis 0 Yes No
7 IT BGCT_ExC#2 Female 14 Ovary 0 Yes No
8 SCST BGCT_ExC#3 Male 3 Testis 0 Yes No
9 IT BGCT_ExC#4 Female 15 Ovary 0 Yes No
10 Simple cyst BGCT_ExC#5 Female 13 Ovary 0 Yes No
11 MT BGCT_ExC#6 Female 0 Sacrococcygeal 0 Yes No
12 IT BGCT_ExC#7 Female 11 Ovary 0 Yes No
13 MT BGCT_ExC#8 Female 11 Ovary 0 Yes No
14 Ganglioglioma B-non-GCT_IC#1 Female 15 CNS 0 Yes Yes
15 Paratesticular RMS M-non-GCT_ExC#1 Male 13 Testis 0 Yes No
16 SCCOHT M-non-GCT_ExC#1 Female 15 Ovary 0 Yes No
17 YST MGCT_ExC#1 Male 2 Testis 0 Yes No
18 MMGCT MGCT_ExC#2 Male 15 Testis 0 Yes No
19 MMGCT MGCT_ExC#3_01 Male 14 Testis 0 Yes No
20 MMGCT MGCT_ExC#3_02 Male 14 Testis 14 Yes No
21 MMGCT MGCT_ExC#3_03 Male 14 Testis 28 Yes No
22 MMGCT MGCT_ExC#3_04 Male 14 Testis 33 Yes No
23 MMGCT MGCT_ExC#3_05 Male 14 Testis 42 Yes No
24 MMGCT MGCT_ExC#3_06 Male 14 Testis 49 Yes No
25 MMGCT MGCT_ExC#3_07 Male 14 Testis 63 Yes No
26 MMGCT MGCT_ExC#3_08 Male 14 Testis 70 Yes No
27 MMGCT MGCT_ExC#3_09 Male 14 Testis 76 Yes No
28 MMGCT MGCT_ExC#3_10 Male 14 Testis 83 Yes No
29 MMGCT MGCT_ExC#3_11 Male 14 Testis 101 Yes No
30 MMGCT MGCT_ExC#3_12 Male 14 Testis 105 Yes No
31 MMGCT MGCT_ExC#3_13 Male 14 Testis 126 Yes No
32 MMGCT MGCT_ExC#3_14 Male 14 Testis 160 Yes No
33 MMGCT MGCT_ExC#3_15 Male 14 Testis 189 Yes No
34 MMGCT MGCT_ExC#3_16 Male 14 Testis 278 Yes No
35 MMGCT MGCT_ExC#3_17 Male 14 Testis 342 Yes No
36 MMGCT MGCT_ExC#3_18 Male 14 Testis 782 Yes No
37 YST MGCT_ExC#4 Female 11 Ovary 4 Yes No
38 YST MGCT_ExC#5 Male 1 Sacrococcygeal 0 Yes No
39 Germinoma MGCT_IC#1 Male 10 CNS 0 Yes No
40 Non-germinoma MGCT_IC#2 Female 13 CNS 0 Yes Yes
41 Germinoma MGCT_IC#3 Female 12 CNS 0 Yes Yes
42 MYCN-amplified
neuroblastoma
M-non-GCT_IC#1 Male 2 CNS At relapse No Yes
Abbreviations: B-non-GCT_IC¼benign non-germ-cell tumour pathology (intracranial); BGCT_ExC¼benign germ-cell tumour (extracranial); CNS¼ central nervous system; CONT¼non-
tumour control samples; CSF¼ cerebrospinal fluid; M-non-GCT_ExC¼malignant non-germ-cell tumour pathology (extracranial); IT¼ immature teratoma; MMGCT¼mixed malignant germ-cell
tumour; MGCT_ExC¼malignant germ-cell tumour (extracranial); MGCT_IC¼malignant germ-cell tumour (intracranial); MT¼mature teratoma; N/A¼ not applicable; RMS¼
rhabdomyosarcoma; SCST¼ sex cord stromal tumour; SCCOHT¼ small cell carcinoma of the ovary, hypercalcaemic type; YST¼ yolk sac tumour.
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not available, volumes were made up to 200 ml with an appropriate
volume of 1 PBS. Total RNA was eluted from columns with
100 ml of nuclease-free water and stored at  80 1C.
Initial QC assessment. Samples were screened for suitability for
use in subsequent qRT–PCR analyses. Initial QC miRNA
assessment was performed for: cel–miR–39–3p (non-human
spike-in); miR–30b–5p (housekeeping miRNA); miR–23a–3p
and miR–451a (used together for haemolysis assessment (Blondal
et al, 2013)). For this initial QC step, miRNA RT and PCRs were
performed in singleplex. Five ml of RNA was reverse transcribed
using the TaqMan miRNA reverse transcription kit (Life
Technologies, Paisley, UK) using the miRNA-specific stem-loop
primer from the relevant TaqMan miRNA assay kit (Life
Technologies; Supplementary Table S1), as per the manufacturer’s
instructions. The final volume of 15 ml for each reaction underwent
RT using a GeneAmp PCR System 9700 (Applied Biosystems,
Warrington, UK) at 16 1C for 30min, 42 1C for 30min, followed by
a final step of 85 1C for 5min, as described previously (Murray
et al, 2011b). A singleplex final PCR was then performed as per the
manufacturer’s instructions. This PCR was performed on a
Mastercycler ep_gradient/S realplex (Eppendorf, Stevenage, UK)
at 95 1C for 10min, followed by 45 cycles of 95 1C for 15 s and
60 1C for one minute, as described previously (Murray et al, 2014).
To exclude non-specific amplification, a no-template control
(NTC) was run for each assay in the QC step. In all cases, no
product was detectable (Figure 1, boxes B1–B3).
Consistency of RNA extraction efficiency between samples
was satisfactory, as measured by cel–miR–39–3p levels (Cq range
19.4–23.7; s.d. 1.28) (Figure 1, box B2 and Supplementary
Figure S1A). Serum levels of the housekeeping miRNA miR–30b–5p
(Murray et al, 2014) were also within the expected range (Cq range
23.7–28.8; s.d. 1.40; Figure 1, box B2 and Supplementary Figure
S1B). Haemolysis assessment was performed using both miR–451a
Cq (Supplementary Figure S1C) and delta Cq (miR–23a–3p minus
miR–451a) values (Figure 1, box B3 and Supplementary Figure
S1D). This assessment showed that 37 of 41 samples (90.2%) had a
delta Cq ofo8 and therefore no substantial evidence of haemolysis
(Blondal et al, 2013); three samples had a borderline delta Cq
value of 8–9 and only a single sample demonstrated haemolysis
(delta Cq 10.2; Supplementary Figure S1D). In the absence of
further replicate non-haemolysed serum samples, we proceeded to
full analysis of these four cases in our evaluation study, but with
appropriate caution regarding the results. This approach allowed
us to study the potential effects of sample haemolysis on candidate
biomarker levels.
MicroRNA quantification. Following initial QC assessment, the
next phase of the pipeline was to quantify expression of a larger
panel of target and housekeeping miRNAs (Supplementary
Table S1). We first performed a multiplexed RT step. The TaqMan
miRNA-specific stem-loop RT primers included those for the eight
main miRNAs from the miR–371–373 and miR–302/367 clusters
(Murray et al, 2011b), plus three miRNA housekeeping genes
previously shown to be most stable in paediatric serum
(namely miR–30b–5p, miR–30c–5p and miR–191–5p (Murray
et al, 2014, 2015b), and the non-human spike-in technical
control cel–miR–39–3p. To ensure sufficient product for the
final PCRs, we performed two identical multiplexed RT
reactions for each sample, using 5ml of RNA eluate in each,
Serum assessment and RNA extraction
1. Exclude visibly haemolysed samples
2. Aliquot 200 l serum
For samples with <200 l serum, make up the volume to
200 l with 1×PBS and record original serum volume
3. Add 5.6×108 copies of cel–miR–39–3p spike-in
control to each sample
4. Process using Qiagen miRNeasy spin column kit
5. Elute RNA with 100 l nuclease-free water
Data analysis
Adjust Cq miR–30b–5p to Cq cel–miR–39–3p
Normalise Cq, target miRNA Cq to miR–30b–5p using
delete delta Cq method
No
Repeat RNA extraction
No
Prepare repeat serum sample
Raw cel–miR–39–3p Cq <25?
Raw miR–30b–5p Cq <30?
miRNA quantification
Multiplexed RT step, multiplexed pre-amplification step
followed by singleplexed final PCR (all TaqMan assays) for
individual test miRNAs, housekeeping miRNAs and
cel–miR–39–3p
Haemolysis assessment:
delta Cq miR–23a–3p – miR–451a <8?
Quality control
Singleplex TaqMan qRT–PCR for
cel–miR–39–3p, miR–30p–5p, miR–23a–3p and miR–451a
Yes
Yes
A
B1
B2
B3
C
D
Figure 1. Pipeline for quantifying miRNA levels in serum using qRT–PCR. For each box (A, B1, B3, C and D), the text in bold describes the
relevant stage of the pipeline. Box B2 describes assessment of RNA extraction efficiency.
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and an equal mixture of the relevant RT primers, adapted from
(Murray et al, 2011b; Supplementary Table S1). The final volume
of 15 ml for each reaction underwent RT, as described above for the
initial QC phase (Figure 1, box C).
Multiplexed pre-amplification of RT product. For the
pre-amplification step, reactions were multiplexed using the
relevant TaqMan assay probes, as described (Murray et al,
2011b). As pre-amplification of specific RT products increases
target abundance without introducing bias (Murray et al, 2011b),
this allowed greater assay sensitivity and increased the number of
target miRNAs measured from the small starting volume. Briefly,
an equal mix of all 20 TaqMan assay probes was prepared for
each reaction and diluted to 0.2 with 1 Tris-EDTA buffer
(pH 8.0), as described previously (Murray et al, 2011b). Two
identical pre-amplification reactions (each 50 ml) for each sample
contained 25 ml of 2 pre-amplification master mix (Life
Technologies), 25 ml of the diluted TaqMan assay probe mix and
12.5 ml of multiplexed cDNA product (Murray et al, 2011b). After
heating to 95 1C for 10min, 14 cycles of 95 1C for 15 s and 60 1C
for 4min were run on the GeneAmp PCR System 9700 (Applied
Biosystems; Murray et al, 2011b). The resulting reaction products
were diluted 1 : 5 with nuclease-free water, and then the two
pre-amplification reaction products for each individual sample
were pooled, to make a final volume of 500 ml, sufficient to
perform all subsequent singleplex final miRNA PCRs in triplicate
(Figure 1, box C).
Final singleplexed PCR of pre-amplification product. Nine ml of
the diluted pre-amplified cDNA product was added to 10 ml of
TaqMan 2 Universal PCR master mix, No AmpErase UNG
(Applied Biosystems) and 1ml of each individual 20 TaqMan
assay probe, thereby maintaining ratios identical to those
previously described (Murray et al, 2011b). All reactions were
performed in triplicate. PCR was performed using the conditions
described above for the initial QC phase. For both the QC
(Figure 1, boxes B1–B3) and the miRNA quantification steps
(Figure 1, box C), the Cq threshold was set manually to 2000
fluorescence units across all PCR plates. NTC samples were also
run in the miRNA quantification step; raw mean NTC Cq values
are listed in Supplementary Table S1. Test miRNAs with results
within two Cq values of the NTC sample or greater were classed as
non-expressing (Figure 1, box C).
Data normalisation and analysis. In the miRNA quantification
step (Figure 1, box C), cel–miR–39–3p and miR–30b–5p were
again measured, to allow assessment of the technical reproduci-
bility of the pipeline. A highly significant correlation was observed
between the Cq values obtained in the initial QC (Figure 1, box B)
and the miRNA quantification steps (Figure 1, box C), for both
cel–miR–39–3p and miR–30b–5p (R2¼ 0.937, Po0.0001 and
R2¼ 0.867, Po0.0001, respectively; Supplementary Figure S1E;
Figure 1, box D).
When analysing the miRNA quantification data (Figure 1, box C),
we first normalised expression of the three endogenous housekeeping
miRNAs miR–30b–5p, miR–30c–5p and miR–191–5p (Murray
et al, 2014, 2015b) to cel–miR–39–3p, in order to account for any
differences in efficiency of the RNA extraction and RT steps. All
three housekeeping miRNAs were found to be stably expressed
across all 41 serum samples (Figure 2A). Importantly, all the
miRNAs used for housekeeping purposes are transcribed from
independent chromosomal loci (miR–30b–5p (chromosomal
locus 8q24); miR–30c–5p (6q13); miR–191–5p (3p21.31) and
miR–23a–3p (19p13.3) (Murray et al, 2015b)). Furthermore, all
have previously been shown to be abundant and stably expressed
in serum from both paediatric and adult (Blondal et al, 2013)
patients. For the four serum samples that showed evidence of
haemolysis (grey arrows in Figure 2A), expression levels of these
three miRNAs still fell within the normal range, demonstrating
their suitability for housekeeping purposes.
By linear regression analysis, levels of cel–miR–39–3p correlated
with each of the three endogenous housekeeping miRNAs,
miR–30b–5p, miR–30c–5p and miR–191–5p (Figure 2B), although
R2 values were only modest, at 0.679, 0.418 and 0.421, respectively.
To confirm that cel–miR–39–3p provided additional stringency
when using the housekeeping miRNAs for data normalisation, we
compared levels of all three with each other, both before
(Figure 2C) and after (Figure 2D) cel–miR–39–3p correction.
Although the three housekeeping miRNAs showed positive
correlations with each other in all comparisons (Po0.0001),
addition of cel–miR–39–3p normalisation increased the R2 values
in all cases (miR–30b–5p vs miR–30c–5p, R2¼ 0.857–0.925;
miR–30b–5p vs miR–191–5p, R2¼ 0.824–0.877; miR–30c–5p vs
miR–191–5p, R2¼ 0.888–0.904; Figure 2C and D).
The s.d. of the serum Cq values across the whole cohort of 41
samples was lowest for miR–30b–5p (1.16), when compared
with miR–30c–5p (1.52) and miR–191–5p (1.51). Consequently,
miR–30b–5p was selected for normalisation of target miRNA
quantification data, following normalisation of the miR–30b–5p
Cq values to the cel–miR–39–3p levels determined in the miRNA
quantification step (Figure 1, box D). Target miRNA levels were
quantified relative to miR–30b–5p using the delta Cq method, as
described previously (Murray et al, 2014, 2015b). For further
details, see Supplementary Materials and Methods. In this
evaluation study we applied very stringent criteria for defining
miRNA overexpression, whereby only serum miRNA levels that
showed a X2.0-fold change in expression (Murray et al, 2014;
Murray et al, 2015b) compared with the highest level from the
non-tumour control group were considered positive. Differences in
serum miRNA levels between experimental groups were assessed
using the Mann-Whitney U-test (Po0.05, significant).
RESULTS
A four-serum miRNA panel (miR–371a–3p, miR–372–3p,
miR–373–3p and miR–367–3p) enables sensitive diagnosis of
paediatric extracranial malignant GCTs. In group comparisons,
normalised levels of four miRNAs were significantly higher in the
serum of paediatric patients with extracranial malignant GCT,
compared with both the combined benign GCT/non-GCT tumour
group and the non-tumour control group (Figure 3A). This panel
comprised the three main miRNAs from the miR–371–373 cluster
(miR–371a–3p, miR–372–3p and miR–373–3p), plus miR–367–3p
from the miR–302/367 cluster. Normalised serum levels of
miR–302a–c were not consistently detected above the control
threshold in malignant GCT patients (data not shown). As
miR–302d–3p levels in all test samples were within two Cq values
of the NTC sample, this miRNA was excluded from subsequent
analyses.
When assessing cases individually, using our highly stringent
criteria for defining miRNA overexpression, positive results were
seen in four out of five extracranial malignant GCTs for
miR–371a–3p; five of five for miR–372–3p; two of five for
miR–373–3p and three of five for miR–367–3p (Figure 3B and
Supplementary Figure S2A–D). There was no obvious association
between test miRNA levels, and the presence of haemolysis in this
small sample set. The greatest dynamic range in levels was seen for
miR–371a–3p, which also showed the clearest separation between
positive and negative samples – for example, the lowest level of
miR–371a–3p observed in a positive sample (MGCT_ExC#3) was
10-fold higher than the highest non-tumour control (CONT_5;
Supplementary Figure S2A). Interestingly, we did not detect
miR–371a–3p overexpression in a serum sample reportedly taken
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at the time of diagnosis of an ovarian YST (MGCT_ExC#4;
Supplementary Figure S2A). Further enquiry revealed that the
sample had in fact been taken 4 days following complete resection
of the ovarian primary tumour, rather than prior to surgery. This is
consistent with the described very short half-life for miR–371a–3p
in the serum, where the major source has been removed
(Dieckmann et al, 2015; Spiekermann et al, 2015a). However,
other members of the four-miRNA panel identified remained
elevated in this serum sample (Supplementary Figure S2).
Together, these observations demonstrated the value of using the
whole panel in detecting extracranial malignant GCTs, including
where the timing of the ‘diagnostic’ serum sample was suboptimal.
In our dataset, miR–372–3p was the only serum miRNA that was
elevated in all cases of extracranial malignant GCT.
Receiver operator characteristic (ROC) analysis, based on
varying cutoffs for defining miRNA overexpression, showed that
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Figure 2. Levels of housekeeping miRNAs in the quantification phase of the pipeline (Figure 1, box C). (A) Cq values for the housekeeping
miRNAs miR–30b–5p, miR–30c–5p and miR–191–5p, obtained after normalisation to cel–miR–39–3p, in all 41 serum samples tested in this study.
Sample numbers correspond to those in Table 1. The four samples that had a delta Cq (miR–23a–3p minus miR–451a) value 48 in the
QC step (Figure 1, box B3) are indicated by arrows. (B) Correlations between the raw Cq values for the housekeeping miRNAs in (A) above
and the raw cel–miR–39–3p Cq values. (C and D) Correlations between the raw (C) and cel–miR–39–3p-normalised (D) Cq values of the three
housekeeping miRNAs in all serum samples tested: miR–30b–5p vs miR–191–5p (left), miR–30c–5p vs miR–191–5p (centre) and miR–30b–5p vs
miR–30c–5p (right).
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each of the four members of the miRNA panel, miR–371a–3p,
miR–372–3p, miR–373–3p and miR–367–3p, were independently
highly sensitive and specific for differentiating paediatric extra-
cranial malignant GCT cases (n¼ 5) from a combined group
(n¼ 15) consisting of both the extracranial benign GCT/non-GCT
tumour cases and the non-tumour control samples (Figure 3C).
We also compared raw Cq (non-normalised) and delta
Cq (normalised) values for the four-serum miRNA panel
(Supplementary Figure S2E), following recent reports suggesting
that relative quantification using normalisation to a housekeeping
miRNA may not be required when quantifying serum miRNAs for
detection of malignant GCTs (Spiekermann et al, 2015b). We
observed a close correlation between raw Cq and delta Cq values
for miR–371a–3p (R2¼ 0.969), but for miR–372–3p, miR–373–3p
and miR–367–3p, the correlation values were lower (R2¼ 0.792,
0.824 and 0.773, respectively; Supplementary Figure S2E).
Serum miRNA levels allow early detection of relapse
during longitudinal follow-up for extracranial (testicular)
malignant GCT. We assessed the value of the miR–371–373
and miR–302/367 cluster miRNAs for early detection of relapse in
malignant GCT. We examined 18 samples obtained during
diagnosis, treatment and follow-up (to day (d) 782) from
a patient with a stage 1 testicular mixed malignant GCT
(Figure 4). For full clinical details of the case, see Supplementary
Results (clinical case 1).
The primary tumour contained YST, EC, CHC and immature
teratoma (IT) components. At the time of diagnosis, the serum
levels of miR–371a–3p, miR–372–3p and miR–367–3p were
elevated (10.1, 2.6- and 2.1-fold, respectively, compared with the
highest non-tumour control (Supplementary Figure S2A–D)).
Seven of the eight main miRNAs (miR–302d–3p excluded) from
the miR–371–373 and miR–302/367 clusters were profiled in 17
further longitudinal serum samples. After resection of the primary
tumour, levels of miR–371a–3p and miR–372–3p decreased to
baseline by d14 (Figure 4C and D, respectively). At the time of
radiologically detected relapse of malignant disease on d28
(Figure 4E), AFP did not increase, while HCG levels showed only
a modest increase of 35.4% from their previous values at d14
(Figure 4A and B, respectively). In striking contrast, miR–371a–3p
increased from a relative level of 25.2 on d14, to 100.3 at d28 (398%
increase) and 220.7 at d33 (876% increase; Figure 4C). Levels of
miR–372–3p also increased at this time, albeit more modestly
(Figure 4D).
Once treatment of the malignant relapse commenced (d33),
levels of miR–371a–3p and miR–372–3p decreased rapidly to
baseline (Figure 4C and D), whereas both AFP and HCG showed
an initial ‘flare’ (observed at d42; Figure 4A and B), before falling to
baseline. Further lymph node enlargement detected radiologically
at the end-of-treatment at d101 was not associated with elevations
of these miRNAs (nor of AFP/HCG; Figure 4). Following
retroperitoneal lymph node dissection (at d140), histopathology
showed a diagnosis of growing teratoma syndrome (a non-
malignant condition; (Logothetis et al, 1982)), rather than further
malignant relapse. In uneventful subsequent clinical follow-up
from d140 to d782, AFP/HCG, miR–371a–3p and miR–372–3p
levels all remained negative (Supplementary Figure S3A). By linear
regression analysis of all 18 longitudinal samples, levels of AFP,
HCG, miR–371a–3p and miR–372–3p each correlated significantly
with the other three markers (Supplementary Figure S3B), with the
strongest correlation being between miR–371a–3p and miR–372–
3p levels (R2¼ 0.909; Po0.0001). Outlier points in the serum
miRNA and AFP/HCG correlations reflected the more pronounced
changes in serum miRNA levels at the time of malignant relapse
(at d28; red arrows in Supplementary Figure S3B) and the lack
of a serum miRNA flare immediately following administration of
chemotherapy (d42; green arrows in Supplementary Figure S3B).
10 000
(i)
(i)
(iii)
(iii)
(iv)
(iv)
(ii)
(ii)
A
B
C
P=0.016
P=0.008
P=0.001
P=0.0013
P= 0.016
P=0.002
P=0.016
P= 0.003
P=0.0005
1000
100
10
1
0.1
0.01
0.001
0.0001
Ma
lign
an
t G
CT
BG
CT
/no
n-G
CT
Co
ntr
ol
R
el
at
ive
 m
iR
–3
71
a–
3p
 le
ve
l
R
el
at
ive
 m
iR
–3
73
–3
p 
le
ve
l
R
el
at
ive
 m
iR
–3
72
–3
p 
le
ve
l
R
el
at
ive
 m
iR
–3
67
–3
p 
le
ve
l
1000
100
10
1
0.1
Ma
lign
an
t G
CT
Ma
lign
an
t G
CT
Ma
lign
an
t G
CT
BG
CT
/no
n-G
CT
BG
CT
/no
n-G
CT
BG
CT
/no
n-G
CT
Co
ntr
ol
Co
ntr
ol
Co
ntr
ol
100 100
10 10
1 1
0.1 0.1
0.01
100
80
60
40
Se
ns
itiv
ity
 (%
)
20 miR–371a–3pAUC=0.97
P=0.004
miR–373–3p
AUC=0.95
P=0.002
miR–377–3p
AUC=0.99
P=0.001
miR–372–3p
AUC=1.00
0
100
80
60
40
Se
ns
itiv
ity
 (%
)
Se
ns
itiv
ity
 (%
)
20
0
100
80
60
40
20
0
100
80
60
40
Se
ns
itiv
ity
 (%
)
20
0
0 20 40 60
100 – Specificity (%) 100 – Specificity (%)
80 100
0 20 40 60
100 – Specificity (%)
80 100 0 20 40 60
100 – Specificity (%)
80 100
0 20 40 60 80 100
0.01
Group Pathology
miR–
371a–3p
miR–
372–3p
miR–
373–3p
miR–
367–3p
Paratesticular RMS
SCCOHT
MT
IT
IT
IT
Cyst
MT
MT
YST
YST
YST
MMGCT
MMGCT
SCST
BGCT_ExC#1
BGCT_ExC#2
BGCT_ExC#3
BGCT_ExC#4
BGCT_ExC#5
BGCT_ExC#6
BGCT_ExC#7
BGCT_ExC#8
Benign GCT
Malignant GCT
MGCT_ExC#1
MGCT_ExC#2
MGCT_ExC#3
MGCT_ExC#4
MGCT_ExC#5
Non-GCT
M-non-GCT_Exc#1
M-non-GCT_Exc#2
Figure 3. Relative levels of serum miRNAs in the quantification phase
of the pipeline (Figure 1, box C) based on samples from patients with
extracranial disease. (A) Levels in the three patient groups of:
(i) miR–371a–3p, (ii) miR–372–3p, (iii) miR–373–3p and (iv) miR–367–3p
by box-and-whisker plot. The broken horizontal line in each graph
represents the cutoffs derived from the serum samples, that is, 2.0
times the highest level seen in the non-tumour control group.
Box¼ interquartile range; whiskers¼ full range of data. (B) Summary
heatmap of levels of each member of the four-miRNA panel in serum
samples from patients at the time of diagnosis of extracranial disease.
Positive results (i.e., miRNA levels X2.0-fold above the highest level
observed in the non-tumour control group) are displayed as black
boxes. For abbreviations, see Table 1. (C) Individual ROC curves for
each member of the four-miRNA panel, namely: (i) miR–371a–3p,
(ii) miR–372–3p, (iii) miR–373–3p and (iv) miR–367–3p. Abbreviation:
AUC¼ area under the curve; ROC¼ receiver operator characteristic.
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Serum and CSF miRNA levels distinguish intracranial malig-
nant GCTs from intracranial non-GCT pathology in paediatric
patients. To determine if the four-miRNA panel comprising
miR–371a–3p, miR–372–3p, miR–373–3p and miR–367–3p could
be used to detect intracranial malignant GCT disease, we measured
the levels of these miRNAs in four serum and four CSF samples,
obtained from a total of five patients (Table 1 and Figure 5). For
full clinical details of these cases, see Supplementary Results
(clinical cases 2).
Serum levels of miR–371a–3p and miR–373–3p were positive at
diagnosis in the intracranial malignant GCT patients MGCT_IC#3
and MGCT_IC#1, respectively (Figure 5B), both of whom had
negative serum and CSF AFP/HCG levels. None of the other
miRNAs tested was positive in the other serum samples, using the
previously specified serum cutoffs. We extracted RNA from CSF of
four patients (MGCT_IC#2, MGCT_IC#3, B-non-GCT_IC#1 and
M-non-GCT_IC#1). The M-non-GCT_IC#1 case was a 2-year-old
male with MYCN-amplified neuroblastoma (Murray et al, 2015b),
who developed intracranial metastatic disease during treatment
(Table 1). In each case, a fixed quantity of non-human spike-in
cel–miR–39–3p was added, as for the serum samples. We
quantified the levels of cel–miR–39–3p, the three housekeeping
miRNAs that we had shown to be stable in the serum (miR–30b–5p,
miR–30c–5p and miR–191–5p), and miR–124–3p, which had
previously been suggested as a suitable CSF housekeeping miRNA
(Exiqon, 2013).
Levels of cel–miR–39–3p recovery from the four CSF
samples obtained in the miRNA quantification step were
equivalent to those observed with the serum sample cohort (mean
Cq cel–miR–39–3p CSF 13.27±s.d. 0.12 vs serum 13.98±s.d. 0.26;
Supplementary Figure S4A). However, miR–124–3p levels showed
a46 Cq difference across the CSF samples. The greatest miR–124–3p
abundance in the CSF was in the MYCN-amplified neuroblastoma
sample (M-non-GCT_IC#1; Supplementary Figure S4A), consistent
with our previous findings that miR–124–3p is a disease-associated
serum biomarker (Murray et al, 2015b). Together, these data
indicate that miR–124–3p is not a good candidate for CSF
normalisation. In contrast, all three of the other housekeeping
miRNAs tested were very stable across the small number of CSF
samples examined, albeit with higher mean Cq values than in the
serum samples (miR–30b–5p, 17.0 vs 14.9; miR–30c–5p, 19.0 vs
15.7 and miR–191–5p, 16.5 vs 13.6, respectively; Supplementary
Figure S4A). Similar to our observations in the serum samples, we
identified that the optimal CSF housekeeping miRNA was
miR–30b–5p, which had a lower s.d. (0.18) than miR–30c–5p
(0.53), miR–191–5p (0.21) and miR–124–3p (3.0; Supplementary
Figure S4A).
As with the serum samples, we also quantified CSF levels of
miR–23a–3p and miR–451a to assess haemolysis (Supplementary
Figure S4B). Despite all four CSF samples being clear and
colourless on visual inspection (i.e., showing no evidence of
haemolysis), two were above the serum haemolysis threshold
(delta Cq 48) using standard methodology (Blondal et al, 2013;
Supplementary Figure S4B). For both miR–451a and miR–23a–3p,
levels in CSF were lower than in haemolysis-negative serum
samples (delta Cq o8, n¼ 37), as indicated by higher mean Cq
values (Supplementary Figure S4B). For several samples, the
elevations in miR–23a–3p Cq values were substantially greater
than those of miR–451a. This indicated that delta Cq (miR–23a–3p
– miR–451a) levels were of limited use in indicating haemolysis
in CSF.
The levels of miR–371–373 and miR–302/367 were then
measured in the three available diagnostic CSF samples from
patients with primary intracranial tumours (MGCT_IC#2,
MGCT_IC#3 and B-non-GCT_IC#1; Figure 5C). The normal-
isation and stringent cutoff procedures used for serum samples
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were applied, with miRNAs that had a X2.0-fold change in
expression compared with the highest serum level from the non-
tumour control group being considered positive. Using these
criteria, CSF miR–371a–3p and miR–372–3p levels clearly
distinguished the intracranial malignant GCTs from the non-
malignant (ganglioglioma) case (Figure 5C). In addition, CSF levels
of miR–373–3p, miR–367–3p, miR–302a–3p and miR–302b–3p
were also positive in the MGCT_IC#3 germinoma case
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(Figure 5C). The raw (non-normalised) Cq values for the
four miRNAs in the panel identified from serum analysis were
similar in the positive and negative CSF samples to those in the
positive and negative serum samples, respectively (Supplementary
Figure S4C), suggesting there was approximate equivalence in the
overall abundance of these miRNAs in serum and CSF.
DISCUSSION
We report a robust, quality controlled pipeline for measuring levels
of specific serum and CSF miRNAs in paediatric patients with
extracranial and intracranial malignant GCTs. The pipeline
benefits from an exogenous non-human spike-in control
(cel–miR–39–3p), normalisation using an endogenous house-
keeping miRNA (miR–30b–5p) and haemolysis quantification
(Blondal et al, 2013). Variation in exogenous cel–miR–39–3p levels
between samples may be reported as differences in Cq values
(Yamada et al, 2014) or recovery rates (Sanders et al, 2012). The
variation we observed in cel–miR–39–3p levels in our cohort, of
B4 Cq cycles, reflects the genuine difference in RNA recovery
between serum samples, which must be normalised to avoid
creating false negative/positive results. This variation is consistent
with other reports (e.g., Yamada et al, 2014) and less than that
described in other studies, which for example, report a recovery
rate of 1–56% (i.e., variation ofB6 Cq values; Sanders et al, 2012).
The correlation data in our relatively small study also indicate
an additional benefit of normalising to a stable, endogenously
expressed miRNA, that is, miR–30b–5p. This second normalisation
step accounts for differences between overall circulating endogen-
ous miRNA levels in individuals, which is not addressed using
cel–miR–39–3p levels alone. Our data indicate that this highly
stringent pipeline, including two normalisation steps, minimises
technical alterations and maximises detection of true biological
variation between serum samples. It will be important for
prospective studies to evaluate the relative contributions of the
two normalisation steps to the avoidance of potential false
negative/positive results. In future, once assessed fully, it may
be possible to relax the proposed normalisation stringency in
circulating miRNA studies.
For CSF analysis, we have shown that miR–30b–5p is stable in a
small cohort of samples, demonstrating minimal variation, and
may therefore also be suitable for normalisation in future CSF
studies. In contrast to previous suggestions (Exiqon, 2013),
miR–124–3p does not appear appropriate as a housekeeping gene
for CSF normalisation and indeed has been identified as a
candidate tumour biomarker in its own right (Murray et al, 2015b).
Haemolysis assessment may also be important during initial
QC, as variations in red blood cell lysis between samples may result
in altered serum expression levels of miRNAs of interest for
technical, rather than biological, reasons (Pritchard et al, 2012).
There are a number of methods for such assessment, including the
measurement of free haemoglobin (Kirschner et al, 2011), or the
established use of delta Cq (miR–23a–3p minus miR–451a) levels
(Blondal et al, 2013; Exiqon, 2013; Ludwig et al, 2015; Murray et al,
2015b). The haemolysis results described here, using the latter
approach, appear comparable in terms of cutoff thresholds to data
obtained utilising different qRT–PCR platforms (Blondal et al,
2013; Ludwig et al, 2015). Haemolysis did not appear to have any
major effect on the levels of our candidate biomarkers from the
miR–371–373 and miR–302/367 clusters, albeit based on a low
sample size. However, as it will be critical to avoid false positive
results when such tests are established in clinical practice, we
recommend that haemolysis assessment should be performed
prospectively in circulating miRNA studies, to define precisely
what effect haemolysis has on candidate biomarkers in borderline
cases. Of note, the miRNA quantification method used to indicate
haemolysis in serum samples was not appropriate for CSF, where
alternative approaches are required.
From our profiling of all eight main members of the miR–371–
373 and miR–302/367 clusters, we derived a panel of four miRNAs
that is capable of accurately detecting both extracranial and
intracranial malignant GCT disease in paediatric patients (see
Supplementary Discussion). Interestingly, the same panel was
shown to be of diagnostic value in adults with testicular malignant
GCTs (Gillis et al, 2013; Syring et al, 2015). In contrast to recent
reports (Dieckmann et al, 2015; Spiekermann et al, 2015a, b),
miR–371a–3p alone was not sufficient to identify some malignant
GCTs in our patient cohort, including in serum from a patient with
an intracranial (pineal) germinoma, where only miR–373–3p
was positive. Moreover, the particularly rapid reduction in
miR–371a–3p levels following tumour removal in stage 1 disease
(Dieckmann et al, 2015; Spiekermann et al, 2015a) will lead to
negative results in samples taken more than 1 day post
surgery, unlike the other miRNAs in the panel. Our data suggest
that expression in body fluids of the four miRNAs in the panel
varies across the spectrum of malignant GCT patients and
that the full panel provides maximal sensitivity, without affecting
specificity. Accordingly, elevated levels of one (or more)
member(s) of the panel would represent a positive test result.
As miR–367–3p is transcribed from a separate chromosome locus
(4q25) to the other three miRNAs from the miR–371–373 cluster
(19q13), elevated serum miR–367–3p levels would add confidence
to a diagnosis of malignant GCT, as distinct from other
malignancies that overexpress miR–371–373 miRNAs but not
miR–367–3p. Such tumours include carcinomas of the stomach
(Liu et al, 2012) and pancreas (He et al, 2014), as well as primary
intracranial tumours with genomic amplification of 19q13 (Pfister
et al, 2009; Korshunov et al, 2010).
We have shown, for the first time, that miRNAs from the four-
serum miRNA panel can sensitively detect malignant GCT relapse
during longitudinal follow-up. In the case studied, miR–371a–3p
and miR–372–3p detected relapse of an AFP/HCG-secreting
(marker-positive) testicular mixed malignant GCT. Indeed, our
data suggest that the miRNAs are more sensitive at detecting
malignant relapse than conventional protein biomarkers, as they
provided a clear positive result at the initial time of radiological
relapse (d28), when HCG levels showed only a modest increase
and AFP levels had not changed. In addition, miR–371a–3p and
miR–372–3p appeared to give a more accurate measure of early
response to therapy, as, unlike AFP and HCG, levels did not flare
following initiation of chemotherapy. Longitudinal monitoring of
further extracranial malignant GCT cases using this panel of
serum miRNAs is likely to demonstrate their clinical utility in the
follow-up of ‘marker-negative’ cases. In due course, serum miRNA
monitoring in malignant GCT patients may reduce the need for
serial CT scans, the associated radiation exposure and second
cancer risk (Tarin et al, 2009).
It has recently been suggested that, it may not be necessary to
perform relative quantification when assessing serum miRNAs as a
potential test for testicular malignant GCTs and that raw Cq values
provide adequate diagnostic discrimination (Spiekermann et al,
2015b). Our data suggest that overall this is a suboptimal approach
when using current methodology. Serum miR–371a–3p has a large
dynamic range, allowing a greater degree of separation between
positive and negative samples in our study. For this miRNA, the
raw Ct (non-normalised) and delta Ct (normalised) values
demonstrated a very strong correlation (R2¼ 0.969). However,
for the other three miRNAs in the four-serum panel (namely
miR–372–3p, miR–373–3p and miR–367–3p), the dynamic range
was lower. The difference in mean Cq value between positive and
negative samples was B4 and the R2 correlation for Cq and delta
Cq values were also lower at 0.792, 0.824 and 0.773, respectively.
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For such miRNAs, differences in RNA extraction efficiency will
have a relatively high impact on PCR measurements and will
require careful control via relative quantification approaches.
Methods that use data normalisation will also enable analysis of
low volume samples (o200 ml), for which dilution is required to
produce a suitable starting volume. Such a scenario is particularly
likely to occur in specimens from paediatric patients and/or certain
sample types, such as CSF.
In due course, robust absolute quantification systems may
supersede relative quantification when measuring miRNA levels in
body fluids (Hindson et al, 2013), although the use of a non-
human spike-in or other appropriate ‘standard’ will still need to be
employed, to ensure the accuracy of RNA extraction steps and
subsequent quantification within and between samples (Sanders
et al, 2012). Determining absolute miRNA counts per set volume of
serum would allow the determination of universal cutoffs, for
example, for miR–451a in assessing haemolysis and for the four-
miRNA panel in diagnosing malignant GCT. This should improve
sensitivity and specificity overall and provide greater confidence in
‘borderline’ cases, ensuring that diagnostic decisions are not
undermined by subtle technical differences. This is important for
translation into the clinic, where minimisation of potential false
negative/positive results is critical.
In conclusion, we have described a robust pipeline for diagnosis
and monitoring of extracranial and intracranial paediatric
malignant GCTs. The technical principles and clinical observations
described here will underpin the future clinical validation work
that is now warranted.
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